New hope to stop lung Cancer's return after surgery
NCT ID NCT02504372
Summary
This large study is testing whether the drug pembrolizumab can help prevent early-stage lung cancer from returning after surgery. It involves over 1,100 patients who have had their cancer surgically removed and completed standard chemotherapy. Participants receive either the active drug or a placebo to see which group stays cancer-free longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.